News | Antiplatelet and Anticoagulation Therapies | August 18, 2016

Antiplatelet Agent Genetic Testing TAILOR-PCI Study Receives $7 Million NHLBI Grant

Study begun in 2013 assessing whether prescribing antiplatelet medication based on genotype will help prevent heart attack, stroke, unstable angina and cardiovascular death in PCI patients

TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant

August 18, 2016 — Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored Antiplatelet Therapy to Lessen Outcomes after Percutaneous Coronary Intervention (TAILOR-PCI) study. This study has received $7 million in additional funding from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). When it began in 2013, TAILOR-PCI included study teams at 15 hospitals from Canada, the United States and South Korea, with a goal of enrolling 5,270 patients. Now, some 29 medical centers are participating, with more expected. The study involves the randomized comparison of clopidogrel bisulfate (Plavix) and ticagrelor (Brilinta), based on genetic testing that identifies resistance to ticagrelor in patients undergoing coronary balloon angioplasty.

The study is examining whether prescribing heart medication based on a patient’s CYP2C19 genotype will help prevent heart attack, stroke, unstable angina and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI). A PCI, commonly known as an angioplasty, is a non-surgical procedure that opens up narrowed or blocked blood vessels in the heart.

“The significance and potential far-reaching impact of a clinical trial of this scope will push the boundaries about the benefits that personalized medicine for patients who undergo a coronary stent procedure can provide,” said Barry Rubin, M.D., medical director, Peter Munk Cardiac Centre, University Health Network (UHN). “The validation provided by the NHLBI through this important grant is further evidence of our leadership role in large-scale cardiovascular studies requiring international clinical trials expertise and a multi-disciplinary team approach,” he said. “This is the largest trial to evaluate a personalized molecular medicine approach to patients with heart disease that has even been carried out.”

The study was launched by Mayo Clinic Center for Individualized Medicine and the Department of Cardiovascular Diseases at Mayo Clinic, in collaboration with the Peter Munk Cardiac Centre, the Applied Health Research Centre at the University of Toronto and Spartan Bioscience, Ottawa.

“This is a multinational collaboration designed to inform clinical practice, in its truest sense,” said Michael Farkouh, M.D., cardiologist, chair, Peter Munk Centre of Excellence in Multinational Clinical Trials and one of two principal investigators of TAILOR-PCl. The other principal investigator is Naveen Pereira, M.D., cardiologist at the Mayo Clinic. “We are delighted to partner with the Mayo Clinic in this effort,” said Farkouh.

“NHLBI is happy to support this important study, which we hope will contribute to the evidence needed to start delivering precision medicine in clinical settings,” said Yves Rosenberg, M.D,. NHLBI program officer for the study, and chief of the Atherothrombosis and Coronary Artery Disease Branch. “This trial could have global impact by potentially changing treatment recommendations for millions of individuals with coronary artery disease needing antiplatelet treatment after a percutaneous coronary intervention.”

Antiplatelet medication has been shown to reduce the risk of heart attack, unstable angina, stroke and cardiovascular death after stent placement by reducing the possibility of blood clots around the site of the surgical incision. The current standard of care after angioplasty is to prescribe clopidogrel for one year.

“Today, we do this regardless of a person’s individual genotype, even though we have known for several years that variation in the CYP2C19 gene may diminish the benefit from the drug,” said Pereira. “What we don’t know — and why there is such confusion in the cardiovascular community — is whether these genetic differences affect long-term clinical outcomes.”

Read the article “Questions Remain on DAPT Prolongation”

For more information: www.petermunkcardiaccentre.ca

Related Content

Videos | 3-D Printing| November 17, 2017
Dee Dee Wang, M.D., Director, Structural Heart Imaging at Henry Ford Hospital, Detroit, explains how her center uses
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension| November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Videos | Stents Bifurcation| November 15, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | TCT| November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
Videos | FFR Technologies| November 15, 2017
A discussion with William Fearon, M.D.
Philips Azurion Image-Guided Therapy Platform Improves Clinical Workflow for Interventional Procedures
News | Angiography| November 15, 2017
Philips announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow...
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Overlay Init